End of Royalty Obligation for Products. On a country-by-country and Product-by-Product basis, [***], Novartis’ obligation to make royalty payments hereunder for such Product in such country will end on the expiration of the Adjusted Payment Period in such country. * ***Confidential Treatment Requested
Appears in 3 contracts
Samples: Option and License Agreement (Akcea Therapeutics, Inc.), Option and License Agreement (Akcea Therapeutics, Inc.), Option and License Agreement (Akcea Therapeutics, Inc.)
End of Royalty Obligation for Products. On a country-by-country and Product-by-Product basis, [***], Novartis’ obligation to make royalty payments hereunder for such Product in such country will end on the expiration of the Adjusted Payment Period in such country. * ***Confidential Treatment RequestedRequested 34
Appears in 1 contract
Samples: Option and License Agreement
End of Royalty Obligation for Products. On a country-by-country and Product-by-Product basis, [***], Novartis’ obligation to make royalty payments hereunder for such Product in such country will end on the expiration of the Adjusted Payment Period in such country. * ***Confidential Treatment Requested.
Appears in 1 contract
Samples: Strategic Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)
